Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c
March 10, 2015 6:45 AM EDT
Both primary efficacy measures successfully achieved in the first of
two Phase 3 clinical trials of OTX-DP for the treatment of post-surgical
ocular inflammation and pain
NDA submission for OTX-DP for the treatment of post-surgical ocular
inflammation and pain expected in 2Q 2015
Initiation of Phase 3 clinical trials of OTX-DP for the treatment of
allergic conjunctivitis expected in the middle of 2015
Phase 2b clinical data on OTX-TP for glaucoma and ocular hypertension
anticipated in 4Q 2015
Conference Call Today at 8:00 am Eastern Time
... More
March 10, 2015 6:30 AM EDT
-- Topline results of the second Phase 3 clinical trial expected
by the end of March --
-- NDA submission anticipated in 2Q 2015 --
BEDFORD, Mass.--(BUSINESS WIRE)--
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced positive topline
data from the first of two Phase 3 clinical trials evaluating the safety
and efficacy of its lead product candidate, OTX-DP (Sustained Release
Dexamethasone), for... More
